Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body. Radiotherapy uses x-rays to target and kill melanoma cells and immunotherapy works by activating the body's own immune system to seek out and fight melanoma cells. Both of these treatments are commonly given to patients with advanced melanoma and other cancers. Both treatments are usually given separately but can also be given together. The aim of this research is to find out if gi

Trial Details

NCT ID
NCT06767306
Phase
PHASE2
Sponsor
Melanoma Institute Australia
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Wollstonecraft, New South Wales, Australia|-33.8328,151.18981
  • Woolloongabba, Queensland, Australia|-27.48855,153.03655
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Female or male patients, age 18 or older
  • Willing to provide signed informed consent
  • Life expectancy \> 6 months
  • First presentation of AJCC Stage IV (any N, M1a, M1b, M1c), histologically confirmed cutaneous, acral or unknown primary melanoma with one to five …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →